Want to see STOK full AI Analyst Report?
Top Page
Stoke Therapeutics
(NASDAQ:STOK)
Select Model
Select Model
Rating:55Neutral
Price Target:
$27.00
▼(-18.40% Downside)
Action:Reiterated
Date:10/21/26
The score is primarily held back by weak financial performance—large TTM losses and renewed heavy cash burn—despite a strong low-debt balance sheet. Technicals are neutral-to-weak (below key longer-term moving averages with negative MACD). Offsetting these factors, the latest earnings call was notably strong on operational progress, regulatory planning, and reported cash runway, which meaningfully supports the overall score.
Positive Factors
Phase III Execution
Completing enrollment ahead of target with no discontinuations strengthens confidence in trial execution and statistical power. It also reduces recruitment uncertainty and supports the planned Q3 2027 readout, an important milestone for advancing zorevunersen toward potential approval.
Negative Factors
Large Losses and Cash Burn
Large recurring losses and renewed heavy cash usage indicate that Stoke is consuming capital rather than compounding it through operations. If this pattern persists, funding needs could rise before product revenue begins, increasing dependence on financing and disciplined spending.
Read all positive and negative factors
Positive Factors
Negative Factors
Phase III Execution
Completing enrollment ahead of target with no discontinuations strengthens confidence in trial execution and statistical power. It also reduces recruitment uncertainty and supports the planned Q3 2027 readout, an important milestone for advancing zorevunersen toward potential approval.
Read all positive factors
Stoke Therapeutics (STOK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.62B
Dividend YieldN/A
Average Volume (3M)1.05M
Price to Earnings (P/E)―
Beta (1Y)1.73
Revenue Growth-86.20%
EPS Growth-476.63%
CountryUS
Employees170
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.36
Shares Outstanding64,526,245
10 Day Avg. Volume1,165,186
30 Day Avg. Volume1,049,822
Financial Highlights & Ratios
PEG Ratio2.85
Price to Book (P/B)5.33
Price to Sales (P/S)10.19
P/FCF Ratio41.85
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue67.78
Enterprise Value/Gross Profit80.05
Enterprise Value/Ebitda-9.02
Forecast
1Y Price Target
$45.11Price Target Upside36.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.64
Revenue Forecast (FY)$32.03M
Stoke Therapeutics Business Overview & Revenue Model
Company Description
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particul...
Stoke Therapeutics Earnings Call Summary
Earnings Call Date:Aug 03, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Positive
The call delivers multiple strong operational and clinical positives: faster-than-expected Phase III enrollment (162 vs target ≥150), 0% discontinuations (vs 15% assumed), robust long-term OLE data (statistically significant Vineland improvements through 4 years, durable seizure reductions), completed manufacturing validation, and a pro forma cash position (~$420M) supporting runway to a potential early-2028 U.S. launch. Key risks are procedural and timing-related rather than clinical safety: SAP and label details are not yet finalized with the FDA, the final Phase III readout and completion of the rolling NDA extend into Q3 2027, inclusion of OLE data in the label is not guaranteed, and diagnosis/access gaps (particularly in adults) and reliance on partner execution outside North America remain challenges. On balance, the positive clinical progress, regulatory preparedness, financial runway, and commercial planning materially outweigh the remaining uncertainties.Positive Updates
Phase III EMPEROR Enrollment Completed Ahead of Target
Enrolled 162 patients in EMPEROR in ~10 months versus an enrollment target of at least 150 (≈8% above target). More than 140 (145) patients have completed week 8 (≈89.5% of enrolled), ~50% have passed week 24, and 60 patients (≈37% of enrolled) have completed the week 28 primary endpoint assessment. No treatment discontinuations to date (0% vs the 15% discontinuation assumed in powering).
Negative Updates
Regulatory and Statistical Details Still Pending
Pre-NDA discussions with FDA will address statistical analysis plan (SAP) and hierarchy/composite approach for Vineland-3 subdomains; exact SAP alignment and how secondary endpoints will be presented remain to be agreed with the agency, introducing some regulatory execution risk.
Read all updates
Q2-2026 Updates
Positive
Negative
Phase III EMPEROR Enrollment Completed Ahead of Target
Enrolled 162 patients in EMPEROR in ~10 months versus an enrollment target of at least 150 (≈8% above target). More than 140 (145) patients have completed week 8 (≈89.5% of enrolled), ~50% have passed week 24, and 60 patients (≈37% of enrolled) have completed the week 28 primary endpoint assessment. No treatment discontinuations to date (0% vs the 15% discontinuation assumed in powering).
Read all positive updates
Company Guidance
The company provided clear operational and regulatory guidance and a number of specific metrics: Phase III EMPEROR enrollment is complete at 162 patients (enrolled in ~10 months) with >140 (145) patients through week 8, ~60 patients through the week‑28 primary endpoint (percent change in major motor seizure frequency), about half through week 24 (one dose left in the 52‑week treatment period), and 0 discontinuations to date; the study is powered (initial target ≥150, powered >90% for Vineland‑3 subdomains with a planned hierarchical/composite secondary analysis) for readout in Q3 2027, with a pre‑NDA meeting in early fall 2026 and a rolling NDA to begin Q1 2027 (CMC first, clinical data to close in Q3 2027) targeting potential FDA approval and U.S. launch in early 2028. Longer‑term data guidance: the company cites statistically significant Vineland improvements through 4 years in the OLE, >930 zorevunersen doses administered, some patients treated >5 years (up to 16 doses over 5 years), 81 Phase I/IIa enrollees with 93% (75) entering the OLE and 57 remaining, and the expectation of ~6 years of Phase I/II + OLE safety/efficacy data available around NDA submission. Financial and commercial guidance: pro forma cash ≈ $420M ($354.3M quarter‑end cash plus $65.7M ATM proceeds) expected to fund operations through a potential U.S. launch, commercial manufacturing validation complete, plan for a lean U.S. commercial footprint (~25 sales reps) to serve an estimated U.S. Dravet population of ~16,000 (≈6,000 ≤25 years immediately addressable) and a global pool of ~38,000 across seven major markets. Near‑term pipeline metrics include an infant/toddler study (<24 months) to start later in 2026, a STK‑002 ADOA Phase I single‑ascending‑dose study with a 3‑patient sentinel cohort (cohort 2 dosing underway; four cohorts planned) and anticipated early safety/efficacy readouts in H1 2027.Stoke Therapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
78
Positive
Cash Flow
35
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 27.59M | 184.42M | 36.55M | 8.78M | 12.40M | 0.00 |
| Gross Profit | 23.36M | 184.42M | 36.55M | 8.78M | 12.40M | 0.00 |
| EBITDA | -207.30M | -5.12M | -86.80M | -102.23M | -99.52M | -84.83M |
| Net Income | -207.90M | -6.88M | -88.98M | -104.70M | -101.07M | -85.81M |
Balance Sheet | ||||||
| Total Assets | 393.97M | 418.43M | 271.56M | 228.34M | 256.07M | 238.87M |
| Cash, Cash Equivalents and Short-Term Investments | 292.82M | 284.67M | 216.90M | 201.39M | 229.59M | 219.81M |
| Total Debt | 2.68M | 3.01M | 4.77M | 2.06M | 2.36M | 5.04M |
| Total Liabilities | 48.42M | 65.98M | 42.53M | 68.78M | 71.22M | 21.09M |
| Stockholders Equity | 345.55M | 352.46M | 229.02M | 159.56M | 184.85M | 217.78M |
Cash Flow | ||||||
| Free Cash Flow | -180.68M | 44.91M | -87.05M | -82.68M | -35.83M | -68.11M |
| Operating Cash Flow | -177.99M | 45.59M | -86.85M | -81.07M | -31.87M | -66.91M |
| Investing Cash Flow | 7.75M | -186.81M | -107.47M | 105.95M | -45.88M | -76.43M |
| Financing Cash Flow | 181.70M | 97.39M | 131.09M | 53.01M | 46.41M | 1.28M |
Stoke Therapeutics Technical Analysis
Negative
33.09
Price Trends
28.02
Negative
29.30
Negative
31.05
Negative
Market Momentum
-0.68
Negative
45.75
Neutral
66.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STOK, the sentiment is Negative. The current price of 33.09 is above the 20-day moving average (MA) of 24.91, above the 50-day MA of 28.02, and above the 200-day MA of 31.05, indicating a neutral trend. The MACD of -0.68 indicates Negative momentum. The RSI at 45.75 is Neutral, neither overbought nor oversold. The STOCH value of 66.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for STOK.
Stoke Therapeutics Risk Analysis
Stoke Therapeutics disclosed 67 risk factors in its most recent earnings report. Stoke Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Stoke Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $1.57B | -3.34 | -57.79% | ― | 12.58% | 28.42% | |
55 Neutral | $1.62B | -7.45 | -59.36% | ― | -86.20% | -476.63% | |
53 Neutral | $1.56B | -5.55 | -111.96% | ― | 30.24% | -3.25% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.29B | -9.37 | -56.19% | ― | -32.27% | -21.09% | |
49 Neutral | $1.87B | -12.31 | -9.96% | ― | -20.44% | -349.84% | |
47 Neutral | $627.19M | -2.92 | -50.12% | ― | -30.42% | -23.31% |
* Healthcare Sector Average
STOK
Stoke Therapeutics
25.04
-7.96
-24.12%
SRPT
Sarepta Therapeutics
17.73
-5.77
-24.55%
QURE
uniQure
22.43
-45.49
-66.98%
WVE
Wave Life Sciences
3.18
-4.44
-58.27%
NTLA
Intellia Therapeutics
11.21
-3.58
-24.21%
TSHA
Taysha Gene Therapies
3.96
-0.92
-18.85%
Stoke Therapeutics Corporate Events
Executive/Board Changes
Stoke Therapeutics appoints new independent board director
Neutral
Sep 25, 2026
On September 22, 2026, Stoke Therapeutics director Edward M. Kaye, M.D. informed the board of his decision to resign as a Class III director and member of the Research and Development Committee, effective September 23, 2026, with the company stati...
Private Placements and FinancingRegulatory Filings and Compliance
Stoke Therapeutics Expands ATM Equity Program for Funding
Neutral
Aug 3, 2026
On August 3, 2026, Stoke Therapeutics filed a prospectus supplement with the SEC to register the potential sale of up to $200 million of common stock under an existing at-the-market equity offering program established with Cantor Fitzgerald in May...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.